As FLASCO has shared, the FDA recently approved Cotellic™ (cobimetinib) for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma for use in combination with Zelboraf® (vemurafenib). With this approval, people with this type of deadly and aggressive skin cancer now have a new targeted option.
Genentech would like to extend an invitation to a webcast that will provide an overview of Cotellic. There will be three webcast sessions to choose from starting this week. Click here for more details.
Session 1: Thursday, December 3, 2015
- Time: 4:00 pm PT | 7:00 pm ET
- Presenter: C. Lance Cowey, MD | Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX
- RSVP here: http://www.medforcereg.net/SGEN3538
Session 2: Tuesday, December 8, 2015
- Time: 9:30 am PT | 12:30 pm ET
- Presenter: Gregory Pennock, MD, FACP | Baptist MD Anderson Cancer Center, Jacksonville, FL
- RSVP here: http://www.medforcereg.net/SGEN3472
Session 3: Thursday, December 10, 2015
- Time: 12:00 pm PT | 3:00 pm ET
- Presenter: Omid Hamid, MD | The Angeles Clinic and Research Institute, Los Angeles, CA
- RSVP here: http://www.medforcereg.net/SGEN3536
This is a promotional program sponsored by Genentech. It is not intended to solicit questions or discussions related to product uses that are not approved by the FDA. No CME credits will be provided. If you have any questions or would like any additional information, please contact Judy Parra, 212-445-8089.
View the Full Event Flyer Here!